|
Oct 24
|
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
|
|
Oct 7
|
Compugen to Present New Clinical Data at SITC 2024
|
|
Aug 29
|
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Aug 26
|
Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
|
|
Aug 7
|
Compugen Ltd. (NASDAQ:CGEN): When Will It Breakeven?
|
|
Aug 6
|
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 6
|
Compugen: Q2 Earnings Snapshot
|
|
Aug 6
|
Compugen Reports Second Quarter 2024 Results
|
|
Jul 30
|
Compugen receives FDA approval for Phase I trial of solid tumour treatment
|
|
Jul 29
|
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
|
|
Jul 23
|
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
|
|
May 15
|
Compugen Appoints David Silberman as Chief Financial Officer
|
|
May 6
|
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
|
|
Apr 29
|
We're Not Worried About Compugen's (NASDAQ:CGEN) Cash Burn
|
|
Apr 25
|
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
|
|
Apr 10
|
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
|
|
Apr 3
|
Compugen to Participate in Two Upcoming Investor Conferences
|
|
Apr 2
|
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 31% Discount?
|
|
Mar 12
|
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
|
|
Mar 11
|
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
|